Vonoprazan

ALIMENTARY TRACT AND METABOLISM

Key facts

Vonoprazan is an onp drug catalogued in DrugCentral. It was first approved by the PMDA in 2014. DrugCentral lists 1 molecular target, including ATP4A|ATP4B. Recorded indications include Duodenal ulcer disease, Erosive esophagitis, Gastric ulcer and Gastro-esophageal reflux disease with esophagitis.

• Approval status: onp (first approved 2014 by the PMDA).
• Molecular targets: ATP4A|ATP4B (1 listed in DrugCentral).
• Indications: Duodenal ulcer disease, Erosive esophagitis, Gastric ulcer, Gastro-esophageal reflux disease with esophagitis and Infection caused by Helicobacter pylori.
• ATC code: A02BC08 (Proton pump inhibitors).
• Molecular formula: C17H16FN3O2S; molecular weight 345.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Duodenal ulcer disease
• Erosive esophagitis
• Gastric ulcer
• Gastro-esophageal reflux disease with esophagitis
• Infection caused by Helicobacter pylori

Contraindications (1)

• Rilpivirine-containing products

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Potassium-transporting ATPase	ATP4A|ATP4B	inhibitor	Ki 8.00

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2023-11-01	FDA	—	PHATHOM
2014-12-26	PMDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
A02BC08	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Proton pump inhibitors
A02BD14	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Combinations for eradication of Helicobacter pylori
A02BD15	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Combinations for eradication of Helicobacter pylori
A02BD17	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Combinations for eradication of Helicobacter pylori

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: CYP2D6 · No Clinical PGx
• FDA label: CYP2C19 · No Clinical PGx
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Interstitial lung disease	356.5
Hepatic function abnormal	300.6
Cerebral infarction	206.3
Renal impairment	197.7
Cardiac failure	160.4
Decreased appetite	144.2
Platelet count decreased	122.8
Neutrophil count decreased	115.9
Pneumonia aspiration	112.6
Immune-mediated enterocolitis	108.5
Pneumonia bacterial	106.3
Pulmonary toxicity	102.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vonoprazan is on its molecule page.

• Molecular formula: C₁₇H₁₆FN₃O₂S
• Molecular weight: 345.39 g/mol
• CAS number: 881681-00-1
• InChIKey: BFDBKMOZYNOTPK-UHFFFAOYSA-N
• PubChem CID: 15981397

CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vonoprazan used for?

DrugCentral lists the following indications for Vonoprazan: Duodenal ulcer disease, Erosive esophagitis, Gastric ulcer, Gastro-esophageal reflux disease with esophagitis and Infection caused by Helicobacter pylori.

How does Vonoprazan work?

Its molecular targets in DrugCentral include ATP4A|ATP4B (inhibitor).

When was Vonoprazan first approved?

Vonoprazan was first approved by the PMDA in 2014.

What is the chemical formula of Vonoprazan?

Vonoprazan has the molecular formula C17H16FN3O2S and a molecular weight of 345.39 g/mol.

Sources

• DrugCentral drug card 4993 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2064032 — compound record and bioactivity
• PubChem CID 15981397 — chemical identifiers
• DrugBank DB11739 — drug record
• FDA UNII 1R5L3J156G — substance identity
• DailyMed: FDA labels for Vonoprazan — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.